RU2003104981A - USE OF SOH-2 INHIBITORS TO PREVENT IMMUNO DEFICIENCY - Google Patents

Claims (27)

1. The use of an inhibitor of COX-2, which inhibits the enzymatic activity of COX-2, or its derivative, or a pharmaceutically acceptable salt for the manufacture of a medicament for the treatment or prevention of HIV infections or infections caused by a related virus or AIDS. 2. The use according to claim 1, where the specified drug is intended for administration to humans, pets or farm animals. 3. The use according to claim 1 or 2, wherein said COX-2 inhibitor has a COX-1: COX-2 selectivity ratio of> 5, preferably> 50, according to the WHMA assay at IC ₈₀ . 4. The use according to any one of claims 1 to 3, wherein said COX-2 inhibitor is methanesulfonamide ether, methanesulfonamide thioether or diarylheterocycle. 5. The use according to any one of claims 1 to 4, wherein said COX-2 inhibitor is a compound of general formula A

where X represents an oxygen or sulfur atom or an alkyl group, preferably a —CH ₂ - group; R ₁ represents a cycloalkyl or aryl group which may be, but is not necessarily, substituted by one or more groups or atoms, preferably one or more halogen atoms; and R ₂ , R ₃ , R ₄ and R ₅ independently represent a hydrogen atom, a nitro or acyl group or an alkyl group which may, but is not necessarily, substituted by one or more groups or atoms, or, alternatively, R ₂ and R ₃ , R ₃ and R ₄ , or R ₄ and R ₅ , taken together with the carbon atom to which they are attached, form a cyclopentanone group, or a derivative thereof, or a pharmaceutically acceptable salt. 6. The use according to claim 5, where X represents an oxygen atom. 7. The use according to claim 5 or 6, where R ₁ represents an aryl group or an aryl group substituted by one or more fluorine atoms, or a cycloalkyl group. 8. The use according to any one of claims 5 to 7, where R ₂ and R ₃ represent hydrogen atoms, and R ₄ represents a group —NO ₂ or —COCH ₃ . 9. The use according to any one of claims 5 to 8, where R ₂ represents a hydrogen atom, and R ₃ and R ₄ taken together form a cyclopentanone group. 10. The use according to any one of claims 5 to 9, wherein said COX-2 inhibitors are flosulide, NS-398, nimesulide, FK 3311 and L-745337. 11. The use according to any one of claims 1 to 4, wherein said COX-2 inhibitor is a compound of general formula B

where Y represents a cyclic group, preferably an oxazolyl, isoxazolyl, thienyl, dihydrofuryl, furyl, pyrrolyl, pyrazolyl, thiazolyl, imidazolyl, isothiazolyl, cyclopentenyl, phenyl and pyridyl group; n is 0 to 3; m is 0 to 4; R ₆ represents a ketocyclyl, cycloalkyl or aryl group, which may be, but is not necessarily, substituted by one or more groups or atoms, preferably one or more halogen atoms; R ₇ each independently represents a substituent, which may be any functional group, preferably a hydrogen or halogen atom or an alkyl group which may be substituted by one or more groups or atoms; R ₈ represents an alkyl group; R ₉ represents a halogen atom; R ₁₀ represents a hydrogen atom or an alkyl group optionally substituted with one or more groups or atoms, preferably an acyl group, or a derivative thereof, or a pharmaceutically acceptable salt. 12. The use according to claim 11, where R ₈ represents NH ₂ - or-CH ₃ . 13. The use according to claim 11 or 12, where Y represents a pyrazolyl, furyl or thienyl group. 14. The use according to any one of claims 11 to 13, wherein R ₆ is an aryl group optionally substituted with one or more fluorine atoms. 15. The use according to any one of paragraphs.11-14, where n = 1 or 2. 16. The use according to any one of claims 11 to 15, where R ₇ preferably represents a bromine atom, an acyl group or a substituted alkyl group. 17. The use according to any one of claims 11-16, wherein said COX-2 inhibitor is celecoxib, rofecoxib, DuP-697, SC-58125, DFP, DFU, CGP 28232 or tricyclic MF. 18. The use according to any one of claims 1 to 4, wherein said COX-2 inhibitor is a derivative of a non-steroidal anti-inflammatory drug (NSAID). 19. The use according to any one of claims 1 to 18, wherein said COX-2 inhibitor is diisopropyl fluorophosphate, L-745337, rofecoxib, NS398, SC58125, etodolac, meloxicam, celecoxib or nimesulide. 20. The use according to claim 19, where the specified COX-2 inhibitor is rofecoxib. 21. The use according to claim 19, where the specified COX-2 inhibitor is celecoxib. 22. The use according to claim 19, where the specified COX-2 inhibitor is meloxicam. 23. A pharmaceutical composition comprising a COX-2 inhibitor that inhibits the enzymatic activity of COX-2, or a derivative thereof, or a pharmaceutically acceptable salt, as defined in any one of claims 1 to 22, and a pharmaceutically acceptable diluent, carrier or excipient for use as a medicament, preferably for treating or preventing a disorder as defined in claim 1 or 2. 24. The pharmaceutical composition according to claim 23, which further comprises one or more additional COX-2 inhibitors, its derivatives or pharmaceutically acceptable salts and / or one or more additional active ingredients. 25. A product comprising a COX-2 inhibitor that inhibits the enzymatic activity of COX-2, or a derivative or pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 22, and one or more additional COX-2 inhibitors, its derivatives or pharmaceutically acceptable salts and / or one or more additional active ingredients in the form of a combined preparation for simultaneous, separate or sequential use for the treatment or prevention of the disorder defined in claim 1 or 2. 26. The use of a pharmaceutical composition as defined in claim 23 or 24 for the manufacture of a medicament for the treatment or prevention of a disorder as defined in claim 1 or 2. 27. A method of treating or preventing a disorder as defined in claim 1 or 2 in a human or animal, wherein a COX-2 inhibitor that inhibits the enzymatic activity of COX-2, or a derivative thereof, or a pharmaceutically acceptable salt, as defined in any from claims 1 to 22, or enter the pharmaceutical composition defined in paragraph 23 or 24.